New indications for BeiGene PD-1 inhibitor for first-line treatment of hepatocellular carcinoma
海角七号
发表于 2024-1-2 20:27:48
354
0
0
On January 2, 2024, Baekje Shenzhou announced its PD-1 inhibitor Baekzeon& Reg; The new indication of (tirizizumab) has been approved by the National Medical Products Administration (NMPA) of China for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC) patients. At this point, 12 indications for tirizizumab have been approved in China.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
- Merck PD-1 inhibitor pembrolizumab's fourth lung cancer indication approved in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- Merck PD-1 inhibitor CRDA approved for the treatment of locally advanced cervical cancer in China
- BeiGene: NASDAQ stock code will be changed to 'ONC'
- BeiGene NASDAQ stock code will be changed to 'ONC'
- BeiGene issues 100000 shares, with an increase of 0.007%
- BeiGene and BeiZeAn are approved for new indications in the United States
- Sanofi's BTK inhibitor is declared for market in China
